ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

ORLANDO – Older AML patients are not typically offered germline genetic testing to assess their inherited risk for myeloid malignancies. However, such testing may provide an opportunity to manage cancer risk in families, as well as evaluate relatives' suitability for donating stem cells, the results of a study presented at the American Society of Hematology annual meeting suggest.